Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Arovella Therapeutics Limited ( (AU:ALA) ) has issued an announcement.
Arovella Therapeutics has rejected a shareholder’s attempt to overhaul its board, declaring a purported notice under section 249D of the Corporations Act invalid and confirming it will not convene a general meeting in response. The company says the proposed resolutions to appoint three new directors cannot be lawfully effected and has invited the requisitioning shareholder to formally withdraw the notice, while noting its efforts to meet the shareholder’s director nominees have so far been declined, underscoring ongoing governance tensions.
The dispute comes as Arovella continues to develop its iNKT cell therapy platform and lead candidate ALA-101, positioning the company within the competitive oncology cell therapy space. The board’s firm stance on the validity of the requisition may provide short-term stability for management’s clinical and strategic plans, but it also highlights potential shareholder activism that could influence future governance and strategic direction.
More about Arovella Therapeutics Limited
Arovella Therapeutics Ltd is an ASX-listed biotechnology company developing an invariant natural killer T (iNKT) cell therapy platform licensed from Imperial College London to treat blood cancers and solid tumours. Its lead product, ALA-101, is an allogeneic CAR19-iNKT cell therapy targeting CD19 and CD1d, with an accepted IND from the U.S. FDA, and the company is also advancing solid tumour programs using CLDN18.2-targeting and IL-12-TM technologies.
Average Trading Volume: 1,054,821
Technical Sentiment Signal: Sell
Current Market Cap: A$104M
See more insights into ALA stock on TipRanks’ Stock Analysis page.